Model for testing immunogenicity of peptides

Details Model for testing immunogenicity of peptides Model for testing immunogenicity of peptides

2005-09-06

2005-09-06

Celsa, Bennett (Department: 1639)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S185100, C514S013800, C514S014800

Reexamination Certificate

active

06939546

ABSTRACT:
Assay methods for determining whether a peptide is likely to be immunogenic are based on a computer modeling of binding to a Class II MHC DR1 receptor. This is confirmed by competitive inhibition binding assays. The peptides are useful for eliciting an immune response for vaccination or the production of antibodies or T-cells.

REFERENCES:
patent: 3540444 (1970-11-01), Moreland
patent: 3773919 (1973-11-01), Boswell
patent: 3788315 (1974-01-01), Laurens
patent: 4166800 (1979-09-01), Fong
patent: 4384975 (1983-05-01), Fong
patent: 4530840 (1985-07-01), Tice et al.
patent: 4542025 (1985-09-01), Tice et al.
patent: 4585482 (1986-04-01), Tice et al.
patent: 4622244 (1986-11-01), Lapka et al.
patent: 4637905 (1987-01-01), Gardner
patent: 4675189 (1987-06-01), Kent et al.
patent: 4798786 (1989-01-01), Tice et al.
patent: 4835139 (1989-05-01), Tice et al.
patent: 4863735 (1989-09-01), Kohn et al.
patent: 4897268 (1990-01-01), Tice et al.
patent: 4938763 (1990-07-01), Dunn et al.
patent: 4941880 (1990-07-01), Burns
patent: 5000886 (1991-03-01), Lawter et al.
patent: 5019096 (1991-05-01), Fox, Jr. et al.
patent: 5059187 (1991-10-01), Sperry et al.
patent: 5064413 (1991-11-01), McKinnon et al.
patent: 5075109 (1991-12-01), Tice et al.
patent: 5102872 (1992-04-01), Singh et al.
patent: 5129825 (1992-07-01), Discko, Jr.
patent: 5133701 (1992-07-01), Han
patent: 5236355 (1993-08-01), Brizzolara et al.
patent: 5278202 (1994-01-01), Dunn et al.
patent: 5290494 (1994-03-01), Coombes et al.
patent: 5360610 (1994-11-01), Tice et al.
patent: 5384133 (1995-01-01), Boyes et al.
patent: 5407609 (1995-04-01), Tice et al.
patent: 5417986 (1995-05-01), Reid et al.
patent: 5424289 (1995-06-01), Yang et al.
patent: 5429822 (1995-07-01), Gresser et al.
patent: 5500228 (1996-03-01), Lawter et al.
patent: 5538739 (1996-07-01), Bodmer et al.
patent: 5639480 (1997-06-01), Bodmer et al.
patent: 5643605 (1997-07-01), Cleland et al.
patent: 5648096 (1997-07-01), Gander et al.
patent: 5650173 (1997-07-01), Ramstack et al.
patent: 5688530 (1997-11-01), Bodmer et al.
patent: 5693343 (1997-12-01), Reid et al.
patent: 5762965 (1998-06-01), Burnett et al.
patent: 5811128 (1998-09-01), Tice et al.
patent: 5814344 (1998-09-01), Tice et al.
patent: 5820883 (1998-10-01), Tice et al.
patent: 5853763 (1998-12-01), Tice et al.
patent: 6309669 (2001-10-01), Setterstrom et al.
patent: 0052510 (1994-10-01), None
Chicz et al , Nature , 358 , (Aug. 27, 1992), 769-768.
Nauss et al, Jornl. of Immunology, vol. 150/ No. 8, Part II, (Apr. 15, 1993).
Busch et al, The Jornl. of Immunology, vol. 147, 4, 1292-98, (8/91).
Tang et al , Jrnl. of Virology, 62(12), 4745-51, (12/88).
Jackson et al, Dept. Res., 4(3), (1991), 114-24.
Rothbard et al, Bacterial Protein Toxins, 261 Bakt. Suppl. 19, (1989), 437-45.
Gilding, Biodegradable polymers for use in surgery-polyglycolic/poly (ac c acid) homo- and copolymers: 1, Polymer, vol. 20, Dec. 1979, pp 1459-1464.
Biotechnology News, Aug. 22, 1997, vol. 17, No. 20, Topical DNA vaccine elicits immune response.
Hall, et al., Purification and Analysis of Colonization Factor Antigen I, Coli Surface Antigen 1, and Coli Surface ANtigen 3 Fimbriae from EnterotoxigenicEscherichia coli, Journal of Bacteriology, Nov. 1989, p6372-6374, vol. 171, No. 11.
Evans, et al. Purification and Characterization of the CFR/I Antigen of EnterotoxigenicEscherichia coli, Infection and Immunity, Aug. 1979, p 738-748, vol. 25.
Karjalainen, et al., Molecular Cloning and Nucleotide Sequence of the Colonization Factor Antigen I Gene ofEscherichia coli, Infection and Immunity, Apr. 1989, p1126-1130, vol. 57.
Jeyanthi, et al., Novel, Burst Free Programmable Biodegradable Microspheres For Controlled Release of Polypeptides, Proceedings Int. Symp. control Release Bioact. Mater. (1996) p351-352/.
Yeh, A novel emulsification-solvent extraction technique for production of protein loaded biodegradable microparticles for vaccine and drug delivery, Journal of Controlled Release, 33 (1005) 437-445.
Yan, Characterization and morphological analysis of protein-loaded poly(lactide-co-glycolide) microparticles prepared by watewr-in-oil-in-water emulsion technique, Journal of Controlled Release, 32 (1994) 231-241.
Wang, et al., Influence of formulation methods on the in vitro controlled release of protein from poly (ester) microspheres Journal of Controlled Release, 17 (1991) 23-32.
Brown, Wonder Drugs' Losing Healing Aura, The Washing Post, Jun. 26, 1995, A section.
Setterstrom, Controlled Release of Antibiotics From biodegradable Microcapsules For Wound infection Control, Chemical Abstracts, 1983, pp215-226.
Perez-Casal, et al., Gene Encoding the Major Subunit of CS1 Pili of Human EnterotoxigenicEscherichia coli, Infection and Immunity, Nov., 1990, p 3594-3600, vol. 58, No. 11.
Jordi, et al., Analysis of the first two genes of the CS1 fimbrial operon in human enterotoxigenicEscherichia coliof serotype 0139: H28, FEMS Microbiology Letters 80, (1991) p265-270.
Tan, et al., Mapping the Antigenic Epitopes of Human Dihydrofolate Reductase by systematic Synthesis of Peptides on solid Supports, The Journal of Biological Chemistry, vol. 265, No. 14, Issue of May 15, pp. 8022-8026 (1990).
McConnel, et al., Antigenic homology within human enterotoxigenicEsherichia colifimbrial colonization factor antigens: CFA/I, coli-surface-associated antigens (CS)1,CS2, CS4 and CS17, FEMS Microbiology Letters 61 (1989) 105-108.
Van der Zee, Efficient mapping and characterization of a T cell epitope by the simultaneous synthesis of multiple peptides, Eur. J. Immunol. 1989, 19: 43-47.
Cassels, et al., Analysis ofEscherichia coliColonization Factor Antigen I Linear B-Cell Epitopes, as Determined by Primate Responses, following Protein Sequence Verification, Infection and Immunity, Jun. 1992, p. 2174-2181, vol. 60, No. 6.
Romagnoli, et al. Peptide-MHC Interaction: A Rational Approach to Vaccine Design, Inter, RE. Immunol. 6, 1990, 00 61-73.
Maister, First Oral AIDS Vaccine Trials Near, BioWorld Today, Tuesday, Apr. 19, 1994, p. 4.
Rognan, et al., Molecular Modeling of an Antigenic Complex Between a Viral Peptide and a Class I Major Histocompatibility Glycoprotein, Proteins Structure, Function and Genetics 13 70-85 (1992).
Brown, A hypothetical model of the foreign antigen biinding site of Class II histocompatibility molecules, Nature, vol. 332, Apr. 28, 1988, p845-850.
The Journal of Immunology, vol. 150, No. 8, Part II, Apr. 1993, Nauss et al., Binding Interactions of Peptides in a Structural Homology Model of the DR1 Class MHC, pp. 41A, Abstract 221.
Nature, vol. 358, Issued Aug. 27, 1992, Chiez et al., Predominant Nturally processed Peptides Bound to HLA DR1 are derived from MHC-related Molecule and are Heterogenous in Size, pp. 764-768.
The Journal of Immunology, vol. 150, No. 2, issued Jan. 15, 1993, Boehncke et al., The Importance of Dominant Negative Effects of Amino Acid Side Chain substitution in Peptide-MHC Molecule Interations and T Cell Recognition, pp. 331-341, see Abstract.
The EMBO Journal, vol. 9, No. 6, issued 1990, jardetsky et al., Peptide binding to HLA-DR1: A Peptide with most residues substituted to alanine retains MHC binding, pp. 1797-1803.
Nature, vol. 332, Apr. 28, 1988, Brown et al., A hypothetical model of the foreign antigen binding site of Class II histocompatibility molecules, pp. 845-850.

Affiliated with

Also associated with

Rating

Model for testing immunogenicity of peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Model for testing immunogenicity of peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Model for testing immunogenicity of peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3409219